These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1910642)

  • 21. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
    Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G; Cao Z; Cooper ME
    Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.
    Kirchengast M
    J Hypertens Suppl; 1997 Mar; 15(2):S27-33. PubMed ID: 9218195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers?
    Kloke HJ; Branten AJ; Huysmans FT; Wetzels JF
    Kidney Int; 1998 Jun; 53(6):1559-73. PubMed ID: 9607186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases.
    Liou HH; Huang TP; Campese VM
    Nephron; 1995; 69(1):41-8. PubMed ID: 7891796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcium antagonists and renal failure progression.
    Robles NR
    Ren Fail; 2008; 30(3):247-55. PubMed ID: 18350443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats.
    Remuzzi A; Imberti O; Puntorieri S; Malanchini B; Macconi D; Magrini L; Bertani T; Remuzzi G
    Am J Physiol; 1994 Dec; 267(6 Pt 2):F1034-44. PubMed ID: 7528985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of antihypertensive agents on proteinuria and renal function.
    Maki DD; Ma JZ; Louis TA; Kasiske BL
    Arch Intern Med; 1995 May; 155(10):1073-80. PubMed ID: 7748051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states.
    Bakris GL
    J Am Soc Nephrol; 1991 Aug; 2(2 Suppl 1):S21-9. PubMed ID: 1932640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium-channel blockers for treatment of diabetic nephropathy.
    Murray KM
    Clin Pharm; 1991 Nov; 10(11):862-5. PubMed ID: 1794222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease.
    Dhaun N; Macintyre IM; Melville V; Lilitkarntakul P; Johnston NR; Goddard J; Webb DJ
    Hypertension; 2009 Jul; 54(1):113-9. PubMed ID: 19506099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal effects of antihypertensive drugs.
    Schlueter WA; Batlle DC
    Drugs; 1989 Jun; 37(6):900-25. PubMed ID: 2667938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
    Ohishi M; Takagi T; Ito N; Terai M; Tatara Y; Hayashi N; Shiota A; Katsuya T; Rakugi H; Ogihara T
    Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of calcium antagonist subclasses on markers of nephropathy progression.
    Bakris GL; Weir MR; Secic M; Campbell B; Weis-McNulty A
    Kidney Int; 2004 Jun; 65(6):1991-2002. PubMed ID: 15149313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of calcium antagonists on hypertension and diabetes in new hypertensive diabetic models.
    Sato T; Nara Y; Note S; Yamori Y
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S192-4. PubMed ID: 2455131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium antagonists and the kidney.
    Loutzenhiser RD; Epstein M
    Am J Hypertens; 1989 Jun; 2(6 Pt 2):154S-161S. PubMed ID: 2665786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR.
    Zhou X; Matavelli LC; Ono H; Frohlich ED
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F871-9. PubMed ID: 15900021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.